Risankizumab induction, maintenance therapy improves clinical remission in UC
10 Sep 2024
byElaine Soliven
Induction and maintenance treatment with risankizumab significantly improved the rates of clinical remission in adults with moderate-to-severe active ulcerative colitis (UC), according to two phase III randomized clinical trials.
Risankizumab induction, maintenance therapy improves clinical remission in UC
10 Sep 2024